By applying intelligent algorithms to detect new drugs in trillions of molecules By using high-tech Cryo-EM to elucidate structures of membrane bound proteins By accelerating structure-based lead discovery to address unmet medical needs
Edinburgh, Scotland, and Villigen, Switzerland, 13 August 2024 – Cumulus Oncology, Europe’s first oncology-focused biotech creation company, announces that, in partnership with its collaborator leadXpro (LXP), key milestones have been achieved in their protein structure driven GPR68 drug discovery project. As a result, Cumulus has licensed the small molecule compounds and associated IP created during […]
Milan, Italy, and Villigen, Switzerland 29th May 2024. Today, we are happy to announce our partnership with Golgi Neurosciences, a pioneering company-creator boutique dedicated to developing therapies for neurodegenerative diseases.Together, we created significant progress with different classes of positive and negative modulators of GPR65, a proton-sensing G protein–coupled receptor (GPCR). This receptor is involved in […]
In partnership with Bayer, leadXpro has generated protein and solved the cryo-EM structure of human TRPV4 in complex with the agonist 4α-PDD, providing novel information about agonist binding to this important drug target.